Anti-Inflammatory Biologics Market Rising in United States | Fortune Business Insights
The global anti-inflammatory biologics market size is expected to reach USD 149.80 billion by 2027, exhibiting a CAGR of 11.0% during the forecast period. The indication of an inflammatory surplus in patients with COVID-19 along with plentiful neutrophils and macrophages will revivify growth prospects for the anti-inflammatory biologics market share during the forecast period. The ongoing trials for anti-tumor necrosis factor (TNF) antibodies in severe cases of autoimmune inflammatory disease such as rheumatoid arthritis, inflammatory bowel disease, or ankylosing spondylitis will aid the speedy expansion of the market during the forecast period, mentioned by Fortune Business Insights, in a report, titled “Anti-Inflammatory Biologics Market Size, Share & Industry Analysis, By Drug Class (Anti-Tumor Necrosis Factor (TNF), Interleukin Antagonists, Janus Kinase (JAK) Inhibitors, Others), By Application (Rheumatoid Arthritis, Psoriasis, and Others), By Route of Administration (Oral and Injection (Subcutaneous and Intravenous)), By Distribution Channel (Hospital Pharmacy Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027” the market size stood at USD 64.84 billion in 2019.
Get
Sample PDF Brochure:
https://www.fortunebusinessinsights.com/enquiry/sample/anti-inflammatory-biologics-market-102733
|
North America |
United States, Canada and Mexico |
|
Europe |
Germany, UK, France, Italy, Russia and Turkey
etc. |
|
Asia-Pacific |
China, Japan, Korea, India, Australia, Indonesia,
Thailand, Philippines, Malaysia and Vietnam etc. |
|
South America |
Brazil, Argentina, Columbia etc. |
|
Middle East & Africa |
Saudi Arabia, UAE, Egypt, Nigeria and South
Africa |
Diseases to Foster Growth
The rising cases of
autoimmune inflammatory diseases such as psoriasis, rheumatoid arthritis,
ankylosing spondylitis, inflammatory bowel diseases, ulcerative colitis, and
others is a key factor driving the anti-inflammatory biologics market.
According to the National Psoriasis Foundation, in 2017, 125 million people
across the world were estimated to have psoriasis. As per the World Health
Organization, Osteoarthritis is one of the ten most disabling diseases in
developed countries, which affects 9.6% of men and 18.0% of women aged over 60
years worldwide. Moreover, the World Health Organization also states 80% of
those with osteoarthritis will have limitations in movement, and 25% cannot
perform their major daily activities of life. Besides, the rapid adoption of
biologics for the treatment of inflammatory diseases will support the market
trajectory in the foreseeable future.
Lack of Awareness regarding Biologics to
Obstruct Market
The lack of
awareness regarding biologics as an effective treatment of psoriasis and
rheumatoid arthritis is a key factor restricting the growth of the market.
Disease-modifying Anti-rheumatic Drugs (DMARDs) such as methotrexate is used as
the first-line of treatment for rheumatoid arthritis. While in psoriasis
topical drugs such as corticosteroids, Vitamin D analogues are used as
first-line of treatment. Whereas, biologics are used as third-line of treatment
for both diseases. The partiality towards Disease-modifying Anti-rheumatic
Drugs and disfavor for biologics will impede the market share during the
forecast period.
Speak To Our Analyst:
About Us:
Fortune Business Insights™ delivers accurate data and innovative
corporate analysis, helping organizations of all sizes make appropriate
decisions. We tailor novel solutions for our clients, assisting them to address
various challenges distinct to their businesses. Our aim is to empower them
with holistic market intelligence, providing a granular overview of the market
they are operating in.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Comments
Post a Comment